Atara CAO to depart July 17; Kevin Sarney appointed interim CFO

Atara Biotherapeutics, Inc.

Yanina Grant-Huerta, Chief Accounting Officer, notified on June 22 that employment ends July 17, 2026.
Board appointed Kevin G. Sarney (CRCFO) as interim CFO effective June 26; he serves as principal financial and accounting officer.
Sarney has over 25 years life science finance experience, previously at PwC and executive roles at public/private life science companies.
Sarney paid through CRCFO consulting; company pays hourly rate; no direct compensation from company.
Consulting agreement terminable on 30 days notice; Sarney enters standard indemnification.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Kevin G. Sarney

interim chief financial officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2026-06-26
Filed: June 26, 2026, 4:15 PM ET

On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026.

Departed

Yanina Grant-Huerta

Chief Accounting Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2026-07-17
Successor: Kevin G. Sarney
Filed: June 26, 2026, 4:15 PM ET

On June 22, 2026, Atara Biotherapeutics, Inc. (the “Company”) notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin G. Sarney was appointed as interim chief financial officer at Atara Biotherapeutics, Inc..

Action: appointed
Role: interim chief financial officer

Exact text from the filing

On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Yanina Grant-Huerta departed as Chief Accounting Officer at Atara Biotherapeutics, Inc..

Action: notified
Role: Chief Accounting Officer

Exact text from the filing

On June 22, 2026, Atara Biotherapeutics, Inc. (the “Company”) notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-285498

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.